DNA, D(3'-AMINO-3'-DEOXY-P-THIO)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-HYDROXY-3-((1-OXOHEXADECYL)AMINO)PROPYL) HYDROGEN PHOSPHOROTHIOATE)
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Children's Oncology Groupnucleic_acidPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cixutumumab National Cancer Institute (NCI) | Phase 2 | BB |
Irinotecan Gradalis, Inc. | Phase 3 | BB |
Irinotecan Gradalis, Inc. | Phase 3 | BB |
Eloxatin National Cancer Institute (NCI) | Phase 2 | BB |
FILGRASTIM M.D. Anderson Cancer Center | Phase 2 | B |
View all 36 →
Same molecule, other indications
DNA, D(3'-AMINO-3'-DEOXY-P-THIO)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-HYDROXY-3-((1-OXOHEXADECYL)AMINO)PROPYL) HYDROGEN PHOSPHOROTHIOATE) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →